RxSight, Inc.
Income Statement
| Line Item | Jul 2026 | Jun 2026 | May 2026 | Mar 2026 | Feb 2026 | Dec 2025 | Oct 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $33.7M | — | $30.9M | — | — | — | $30.3M |
| Cost of Revenue | — | $7.9M | — | $7.4M | — | — | — | $6.1M |
| Gross Profit | — | $25.9M | — | $23.5M | — | — | — | $24.2M |
| Gross Margin | — | 76.7% | — | 76.1% | — | — | — | 79.9% |
| Operating Expenses | ||||||||
| Research & Development | — | $9.2M | — | $9.5M | — | — | — | $9.1M |
| SG&A Expense | — | $30.4M | — | $31.9M | — | — | — | $27.3M |
| Operating Income | — | $-13.8M | — | $-17.8M | — | — | — | $-12.2M |
| Operating Margin | — | -40.8% | — | -57.7% | — | — | — | -40.1% |
| Interest Expense | — | $3.0K | — | $3.0K | — | — | — | $4.0K |
| Pretax Income | — | $-12.0M | — | $-15.9M | — | — | — | $-9.8M |
| Income Tax Expense | — | $88.0K | — | $6.0K | — | — | — | $10.0K |
| Net Income | — | $-12.1M | — | $-15.9M | — | — | — | $-9.8M |
| Net Margin | — | -35.9% | — | -51.4% | — | — | — | -32.4% |
| EPS (Basic) | — | $-0.29 | — | $-0.38 | — | — | — | $-0.24 |
| EPS (Diluted) | — | $-0.29 | — | $-0.38 | — | — | — | $-0.24 |
| Shares Outstanding (Basic) | 41.6M | 41.5M | 41.4M | 41.3M | 41.3M | 41.2M | 41.1M | 41.0M |
| Shares Outstanding (Diluted) | 41.6M | 41.5M | 41.4M | 41.3M | 41.3M | 41.2M | 41.1M | 41.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |